This strategy employs the co-encapsulation of disulfiram (DSF), an ALDH1L1 inhibitor, and shikonin (SHK), a PKM2 inhibitor, to comprehensively suppress the tumor's energy supply. This evidence concerns the gene PKM and neoplasm.